Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies

Endocrine Reviews

Volumn 27, Issue 6, 2006, Pages 575-605

  Turgeon, Judith L ^a   Carr, Molly C ^b   Maki, Pauline M ^c   Mendelsohn, Michael E ^d   Wise, Phyllis M ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ANDROGEN; CALCIUM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTISONE; DROSPIRENONE; EPLERENONE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; GESTAGEN; HYDROCORTISONE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MINERALOCORTICOID RECEPTOR; NOMEGESTROL; NORELGESTROMIN; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SOMATOMEDIN C; SPIRONOLACTONE; UNINDEXED DRUG; VITAMIN D;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; DIET THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; HEALTH STATUS; HEART MUSCLE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; ISCHEMIC HEART DISEASE; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; PROGESTINS;

EID: 33750042898     PISSN: 0163769X     EISSN: 0163769X     Source Type: Journal    
DOI: 10.1210/er.2005-0020     Document Type: Review

References (418)

1. Sherwin BB 2002 Estrogen and cognitive aging in women. Trends Pharmacol Sci 23:527-534
2. Paganini-Hill A 2001 Hormone replacement therapy and stroke: risk, protection or no effect? Maturitas 38:243-261
3. Turgeon JL, McDonnell DP, Martin KA, Wise PM 2004 Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304:1269-1273
4. Behl C 2002 Oestrogen as a neuroprotective hormone. Nat Rev Neurosci 3:433-442
5. Roof RL, Hall ED 2000 Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma 17:367-388
6. Dhandapani KM, Brann DW 2002 Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 67:1379-1385
7. McCullough LD, Hurn PD 2003 Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol Metab 14:228-235
8. Wise PM, Dubal DB, Wilson ME, Rau SW, Liu Y 2001 Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol 22:33-66
9. Wise PM, Dubal DB, Rau SW, Brown CM, Suzuki S 2005 Are estrogens protective or risk factors in brain injury and neurodegeneration: reevaluation after the Women's Health Initiative. Endocr Rev 26:308-312
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
12. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
13. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI 2001 A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243-1249
14. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Garnst A, Grundman M, Thomas R, Thal LJ 2000 Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 283:1007-1015
15. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR 2000 Estrogen for Alzheimer's disease in women. Randomized, double-blind, placebo-controlled trial. Neurology 54:295-301
16. Marder K, Sano M 2000 Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do? Neurology 54:2035-2037
17. Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, Yu HY, Wang SJ, Liu HC 2000 Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 54:2061-2066
18. Kopernik G, Shoham Z 2004 Tools for making correct decisions regarding hormone therapy. Part II. Organ response and clinical applications. Fertil Steril 81:1458-1477
19. Shoham Z, Kopernik G 2004 Tools for making correct decisions regarding hormone therapy. Part I. Background and drugs. Fertil Steril 81:1447-1457
20. McDonnell DP 2005 The molecular determinants of estrogen receptor pharmacology. Maturitas 48:S7-S12
21. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
22. Beekman JM, Allan GF, Tsai SY, O'Malley BW 1993 Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7:1266-1274
23. Hall JM, McDonnell DP, Korach KS 2002 Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol Endocrinol 16:469-486
24. Kong EH, Pike AC, Hubbard RE 2003 Structure and mechanism of the oestrogen receptor. Biochem Soc Trans 31:56-59
25. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Change C-Y, Ballas LM, Hamilton PT, McDonnell DP 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β. Proc Natl Acad Sci USA 96:3999-4004
26. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
27. Giangrande PH, McDonnell DP 1999 The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Rec Prog Hormone Res 54:291-313
28. Gustafsson JA 2003 What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol Sci 24:479-485
29. Hall JM, Couse JF, Korach KS 2001 The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276:36869-36872
30. Harris HA, Albert LM, Leathurby Y, Malamus MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Shu Y, Keith Jr JC 2003 Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144:4241-4249
31. Jacobsen BM, Richer JK, Sartorius CA, Horwitz KB 2003 Expression profiling of human breast cancers and gene regulation by progesterone receptors. J Mammary Gland Biol Neoplasia 8:257-268
32. Li X, O'Malley BW 2003 Unfolding the action of progesterone receptors. J Biol Chem 278:39261-39264
33. Smith LH, Coats SR, Qin H, Petrie MS, Covington JW, Su M, Eren M, Vaughan DE 2004 Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor α and estrogen receptor β in endothelial cells. Circ Res 95:269-275
34. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS 2004 Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 145:3473-3486
35. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, Norris JD 2002 Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Rec Prog Hormone Res 57:295-316
36. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 15:1262-1272
37. Sun J, Baudry J, Katzenellenbogen JA, Katzenellenbogen BS 2003 Molecular basis for the subtype discrimination of the estrogen receptor-β-selective ligand, diarylpropionitrile. Mol Endocrinol 17:247-258
38. Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzemeier KH 2004 Dissecting physiological roles of estrogen receptor α and β with potent selective ligands from structure-based design. Mol Endocrinol 18:1599-1609
39. Mulac-Jericevic B, Conneely OM 2004 Reproductive tissue selective actions of progesterone receptors. Reproduction 128:139-146
40. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB 2002 Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277:5209-5218
41. Zhi L, Tegley CM, Pio B, Edwards JP, Motamedi M, Jones TK, Marschke KB, Mais DE, Risek B, Schrader WT 2003 5-Benzylidene-1,2-dihydrochromeno[3,4-f] quinolines as selective progesterone receptor modulators. J Med Chem 46:4104-4112
42. α activity in vivo. J Biol Chem 278:6912-6920
43. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
44. Wessler S, Otto C, Wilck N, Stangl V, Fritzemeier KH 2006 Identification of estrogen receptor ligands leading to activation of nongenomic signaling pathways while exhibiting only weak transcriptional activity. Mol Biol 98:25-35
45. Simoncini T, Genazzani AR 2003 Non-genomic actions of sex steroid hormones. Eur J Endocrinol 148:281-292
46. Edwards DP 2005 Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67:335-376
47. Hersh AL, Stefanick ML, Stafford RS 2004 National use of post-menopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53
48. Dey M, Lyttle CR, Pickar JH 2000 Recent insights into the varying activity of estrogens. Maturitas 34(Suppl 2:S25-S33
49. Kuhl H 2005 Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 8(Suppl 1):3-63
50. Bhavnani BR 2003 Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 85:473-482
51. Ansbacher R 2001 The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 184:255-263
52. Baracat E, Haidar M, Lopez FJ, Pickar J, Dey M, Negro-Vilar A 1999 Estrogen activity and novel tissue selectivity of Δ8,9-dehydroestrone sulfate in postmenopausal women. J Clin Endocrinol Metab 84:2020-2027
53. Rosano GM, Vitale C, Silvestri A, Fini M 2003 Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas 46(Suppl 1):S17-S29
54. Sitruk-Ware R 2002 Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 9:6-15
55. Hapgood JP, Koubovec D, Louw A, Africander D 2004 Not all progestins are the same: implications for usage. Trends Pharmacol Sci 25:554-557
56. Miller AP, Chen Y-F, Xing D, Feng W, Oparil S 2003 Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 42:657-663
57. Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K 1997 Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3:324-327
58. 2+ release mechanism of primate drug-induced coronary vasospasm. Am J Physiol 272:H2645-H2654
59. Nilsen J, Brinton RD 2003 Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA 100:10506-10511
60. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kishimoto T, Kasayama S 2001 Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 21:243-248
61. Simoncini T, Mannella P, Fornari L, Caruso A, Willis MY, Garibaldi S, Baldacci C, Genazzani AR 2004 Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145:5745-5756
62. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM 1999 Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 84:4055-4061
63. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB 2001 Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 104:2826-2831
64. Koubovec D, Berghe WV, Vermeulen L, Haegeman G, Hapgood JP 2004 Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221:75-85
65. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP 2005 Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol 242:23-32
66. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, Wilson EM 1999 Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13:440-454
67. Krattenmacher R 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62:29-38
68. Jaffe IZ, Mendelsohn ME 2005 Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 96:643-650
69. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709-717
70. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
71. Mendelsohn ME 2005 In hypertension, the kidney is not always the heart of the matter. J Clin Invest 115:840-844
72. Schriffin EL 2006 Effects of aldosterone on the vasculature. Hypertension 47:312-318
73. Jewelewicz R 1997 New developments in topical estrogen therapy. Fertil Steril 67:1-12
74. Rosano GM, Simon T, Mercuro G, Sans S, Schenck-Gustaffson K, Stevenson JC, Swahn E, Jaillon P 2001 Hormone replacement therapy: where we stand in Europe. Eur Heart J 22:439-441
75. Scarabin P-Y, Oger E, Plu-Bureau G 2003 Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362:428-432
76. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO 1996 Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 81:2250-2256
77. Pirwany IR, Sattar N, Greer IA, Packard CJ, Fleming R 2002 Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles. Hum Reprod 17:825-829
78. Leung KC, Johannsson G, Leong GM, Ho KK 2004 Estrogen regulation of growth hormone action. Endocr Rev 25:693-721
79. Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. JAMA 273:199-208
80. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T 2002 Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 105:1436-1439
81. Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin J-M, Aiach M, Ochat N, Scarabin P-Y 2004 Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost 2:1594-1600
82. Gomes MP, Deitcher SR 2004 Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 164:1965-1976
83. Godsland IF 2001 Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75:898-915
84. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG 2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854
85. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM 2004 The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498-1501
86. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH 1987 Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110
87. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK 2004 Impaired endothelial function in young women with premature ovarian failure: Normalization with hormone therapy. J Clin Endocrinol Metab 89:3907-3913
88. Mercuro G, Zoncu S, Saiu F, Mascia M, Melis GB, Rosano GM 2004 Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 47:131-138
89. Mikkola TS, Clarkson TB 2002 Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 53:605-619
90. Stevenson JC, Whitehead MI 2002 Hormone replacement therapy. BMJ 325:113-114
91. Anstead GM, Carlson KE, Katzenellenbogen JA 1997 The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268-303
92. Cheskis BJ, Karathanasis S, Lyttle CR 1997 Estrogen receptor ligands modulate its interaction with DNA. J Biol Chem 272:11384-11391
93. Hyder SM, Chiappetta C, Stancel GM 1999 Synthetic estrogen 17α-ethinyl estradiol induces pattern of uterine gene expression similar to endogenous estrogen 17β-estradiol. J Pharmacol Exp Ther 290:740-747
94. Goebelsmann U, Mashchak CA, Mishell Jr DR 1985 Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 151:868-877
95. Abrams LS, Skee D, Natarajan J, Wong FA 2002 Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril 77:S3-S12
96. Lobo RA, Cassidenti DL 1992 Pharmacokinetics of oral 17 β-estradiol. J Reprod Med 37:77-84
97. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP 2002 Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22:201-210
98. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR 2001 Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527-1535
99. Leiden mutation: a randomized trial. Blood 103:927-933
100. Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Kerlan V, Collet M, Abgrall J-F, Aiach M, Scarabin P-Y, Mottier D 2003 Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 23:1671-1676
101. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM 2001 Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 115:415-420
102. Baillargeon JP, McClish DK, Essah PA, Nestler JE 2005 Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863-3870
103. Esmon CT 2004 Crosstalk between inflammation and thrombosis. Maturitas 47:305-314
104. Viles-Gonzalez JF, Fuster V, Badimon JJ 2005 Thrombin/inflammation paradigms: a closer look at arterial and venous thrombosis. Am Heart J 149:S19-S31
105. Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J 2005 Transdermal estradiol does not impair hemostatic biomarkers in postmenopausal women. Maturitas 50:39-43
106. Post MS, Christella M, Thomassen LG, van der Mooren MJ, van Baal WM, Rosing J, Kenemans P, Stehouwer CD 2003 Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol 23:1116-1121
107. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC 2005 Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72:168-174
108. Hayden M, Ghosh S 2004 Signaling to NF-βB. Genes Dev 18:2195-2223
109. Kumar A, Takada Y, Boriek AM, Aggarwal BB 2004 Nuclear factor-βB: its role in health and disease. J Mol Med 82:434-448
110. Varfolomeev EE, Ashkenazi A 2004 Tumor necrosis factor: an apoptosis juNKie? Cell 116:491-497
111. Kaminska B 2005 MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754:253-262
112. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS 2002 A central role for JNK in obesity and insulin resistance. Nature 420:333-336
113. Bogdan C 2001 Nitric oxide and the immune response. Nat Immun 2:907-916
114. Guzik TJ, Korbut R, Adamek-Guzik T 2003 Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54:469-487
115. Karpuzoglu E, Fenaux JB, Phillips RA, Lengi AJ, Elvinger F, Ansar Ahmed S 2006 Estrogen up-regulates inducible nitric oxide synthase, nitric oxide, and cyclooxygenase-2 in splenocytes activated with T cell stimulants: role of interferon-γ. Endocrinology 147:662-671
116. Pfeilschifter J, Koditz R, Pfohl M, Schatz H 2002 Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119
117. Vegeto E, Belcredito S, Ghisletti S, Meda C, Etteri S, Maggi A 2006 The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 147:2263-2272
118. Dimayuga FO, Reed JL, Carnero GA, Wang C, Dimayuga ER, Dimayuga VM, Perger A, Wilson ME, Keller JN, Bruce-Keller AJ 2005 Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. J Neuroimmunol 161:123-136
119. Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, Maggi A 2003 Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 100:9614-9619
120. Xing D, Miller A, Novak L, Rocha R, Chen YF, Oparil S 2004 Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109:234-241
121. Stein B, Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol 15:4971-4979
122. Ghisletti S, Meda C, Maggi A, Vegeto E 2005 17β-estradiol inhibits inflammatory gene expression by controlling NF-κB intracellular localization. Mol Cell Biol 25:2957-2968
123. Kalaitzidis D, Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 16:46-52
124. Chadwick CC, Chippari S, Matelan E, Borges-Marcucci L, Eckert AM, Keith Jr JC, Albert LM, Leathurby Y, Harris HA, Bhat RA, Ashwell M, Trybulski E, Winneker RC, Adelman SJ, Steffan RJ, Harnish DC 2005 Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci USA 102:2543-2548
125. Baker AE, Brautigam VM, Watters JJ 2004 Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor β. Endocrinology 145:5021-5032
126. Grohe C, Kann S, Fink L, Djoufack PC, Paehr M, van Eickels M, Vetter H, Meyer R, Fink KB 2004 17 β-estradiol regulates nNOS and eNOS activity in the hippocampus. Neuroreport 15:89-93
127. Schulz E, Anter E, Zou MH, Keaney Jr JF 2005 Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 111:3473-3480
128. Kershaw EE, Flier JS 2004 Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556
129. Flier JS 2004 Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337-350
130. Lyon CJ, Law RE, Hsueh WA 2003 Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 144:2195-2200
131. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S 2005 Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288:H2031-H2041
132. Rajala MW, Scherer PE 2003 Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-3773
133. Hansson GK 2005 Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
134. Goldstein BJ, Scalia R 2004 Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89:2563-2568
135. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, Wang F, Hull RL, Boyko EJ, Retzlaff BM, Walden CE, Knopp RH, Kahn SE 2002 The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005-1015
136. Wajchenberg BL 2000 Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738
137. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE 1998 Abdominal adiposity and coronary heart disease in women. JAMA 280:1843-1848
138. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364:937-952
139. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S 1998 The metabolically obese, normal-weight individual revisited. Diabetes 47:699-713
140. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EAH, Poehlman ET 2001 What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 86:1020-1025
141. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, Mohammed BS 2004 Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 350:2549-2557
142. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, Scherer P, Rossetti L, Barzilai N 2002 Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2951-2958
143. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I 2005 Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426-430
144. Hug C, Lodish HF 2005 Medicine. Visfatin: a new adipokine. Science 307:366-367
145. Sethi JK, Vidal-Puig A 2005 Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 11:344-347
146. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866
147. Seckl JR, Walker BR 2004 11β-Hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends Endocrinol Metab 15:418-424
148. Hauner H, Schmid P, Pfeiffer EF 1987 Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 64:832-835
149. Hewitt KN, Walker EA, Stewart PM 2005 Minireview: hexose-6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 146:2539-2543
150. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR 2004 Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931-938
151. Enzi G, Gasparo M, Biondetti PR, Fiore D, Semisa M, Zurlo F 1986 Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 44:739-746
152. Mayes JS, Watson GH 2004 Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 5:197-216
153. Belanger C, Luu-The V, Dupont P, Tchernof A 2002 Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 34:737-745
154. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM, Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR 1997 Aromatase expression in health and disease. Rec Prog Hormone Res 52:185-213
155. Yang K, Khalil MW, Strutt BJ, Killinger DW 1997 11 β-Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. J Steroid Biochem Mol Biol 60:247-253
156. Tchernof A, Desmeules A, Richard C, Laberge P, Daris M, Mailloux J, Rheaume C, Dupont P 2004 Ovarian hormone status and abdominal visceral adipose tissue metabolism. J Clin Endocrinol Metab 89:3425-3430
157. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD 2005 Estrogen - the good, the bad, and the unexpected. Endocr Rev 26:322-330
158. Carr MC 2003 The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 88:2404-2411
159. Jensen J, Nilas L, Christiansen C 1990 Influence of menopause on serum lipids and lipoproteins. Maturitas 12:321-331
160. Bruschi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG 1996 Lipoprotein(a) and other lipids after oophorectomy and estrogen replacement therapy. Obstet Gynecol 88:950-954
161. Kanaley JA, Sames C, Swisher L, Swick AG, Ploutz-Snyder LL, Steppan CM, Sagendorf KS, Feiglin D, Jaynes EB, Meyer RA, Weinstock RS 2001 Abdominal fat distribution in pre- and post-menopausal women: the impact of physical activity, age, and menopausal status. Metabolism 50:976-982
162. Guthrie JR, Dennerstein L, Dudley EC 1999 Weight gain and the menopause: a 5-year prospective study. Climacteric 2:205-211
163. Carr MC, Brunzell JD, Increased hepatic lipase activity and intraabdominal fat across the transition from pre- to postmenopause. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, 2003, p 374 (Abstract P2-280)
164. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR 1989 Menopause and risk factors for coronary heart disease. N Engl J Med 321:641-646
165. Blumel JE, Castelo-Branco C, Rocangliolo ME, Bifa L, Tacla X, Mamani L 2001 Changes in body mass index around menopause: a population study of Chilean woman. Menopause 8:239-244
166. Bjorkelund C, Lissner L, Andersson S, Lapidus L, Bengtsson C 1996 Reproductive history in relation to relative weight and fat distribution. Int J Obes Relat Metab Disord 20:213-219
167. Key TJ, Allen NE, Verkasalo PK, Banks E 2001 Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 60:81-89
168. Santoro N, Lasley B, McConnell D, Allsworth J, Crawford S, Gold EB, Finkelstein JS, Greendale GA, Kelsey J, Korenman S, Luborsky JL, Matthews K, Midgley R, Powell L, Sabatine J, Schocken M, Sowers MF, Weiss G 2004 Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. J Clin Endocrinol Metab 89:2622-2631
169. Verkasalo PK, Thomas HV, Appleby PN, Davey GK, Key TJ 2001 Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and post-menopausal women (United Kingdom). Cancer Causes Control 12:47-59
170. Misso ML, Jang C, Adams J, Tran J, Murata Y, Bell R, Boon WC, Simpson ER, Davis SR 2005 Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause 12:210-215
171. Norman RJ, Flight IH, Rees MC 2000 Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev (2):CD001018
172. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM 2004 Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 103:359-373
173. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A 1995 Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil Steril 63:516-521
174. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK, Greendale GA 1997 Effect of post-menopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. J Clin Endocrinol Metab 82:1549-1556
175. Mattiasson I, Rendell M, Tornquist C, Jeppsson S, Hulthen UL 2002 Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Horm Metab Res 34:583-588
176. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV 2004 Effect of oestrogen plus progestin on the incidence of diabetes in post-menopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 47:1175-1187
177. Cooke PS, Naaz A 2004 Role of estrogens in adipocyte development and function. Exp Biol Med 229:1127-1135
178. D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS 2005 Estrogen regulation of adiposity and fuel partitioning: Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways. J Biol Chem 280:35983-35991
179. Sites CK, L'hommedieu GD, Toth MJ, Brochu M, Cooper BC, Fairhurst PA 2005 The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 90:2701-2707
180. Wisse BE 2004 The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15:2792-2800
181. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante Jr AW 2003 Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
182. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH 1998 Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731-733
183. Venugopal SK, Devaraj S, Jialal I 2005 Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 14:33-37
184. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, Wallace RB, Jackson RD, Pettinger MB, Ridker PM 2002 Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288:980-987
185. Shaywitz SE, Naftolin F, Zelterman D, Marchione KE, Holahan JM, Palter SF, Shaywitz BA 2003 Better oral reading and short-term memory in midlife, postmenopausal women taking estrogen. Menopause 10:420-426
186. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GA, Schunkert H 2000 Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab 85:1340-1344
187. Uhlar CM, Whitehead AS 1999 Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501-523
188. Hu P, Greendale GA, Palla SL, Reboussin BA, Herrington DM, Barrett-Connor E, Reuben DB 2006 The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women. The Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185:347-352
189. Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM 2005 Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 93:1108-1116
190. Davison S, Davis SR 2003 New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 88:2470-2478
191. Cheleuitte D, Mizuno S, Glowacki J 1998 In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 83:2043-2051
192. Rogers A, Eastell R 2001 The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood. Bone 29:30-34
193. Chait A, Han CY, Oram JF, Heinecke JW 2005 Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46:389-403
194. Connelly PW, Hanley AJ, Harris SB, Hegele RA, Zinman B 2003 Relation of waist circumference and glycemic status to C-reactive protein in the Sandy Lake Oji-Cree. Int J Obes Relat Metab Disord 27:347-354
195. Abbas A, Fadel PJ, Wang Z, Arbique D, Jialal I, Vongpatanasin W 2004 Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in post-menopausal women. Arterioscler Thromb Vasc Biol 24:e164-e167
196. Miller VM, Shuster LT, Hayes SN 2003 Controversy of hormone treatment and cardiovascular function: need for strengthened collaborations between preclinical and clinical scientists. Curr Opin Investig Drugs 4:1220-1232
197. 2005 Biology of perimenopause: impact on health and aging workshop summary report. Bethesda, MD: National Institute on Aging/National Institutes of Health. http://www.nia.nih.gov/ResearchInformation/ConferencesAndMeetings/ Biology+of+the+Perimenopause+-+Impact+on+Health+and+Aging+Workshop.htm
198. McDonnell DP 1999 The molecular pharmacology of SERMs. Trends Endocrinol Metab 10:301-311
199. Mendelsohn ME, Karas RH 1994 Estrogen and the blood vessel wall. Curr Opin Cardiol 9:619-626
200. Farhat MY, Lavigne MC, Ramwell PW 1996 The vascular protective effects of estrogen. FASEB J 10:615-624
201. Mendelsohn ME, Karas RH 1999 Mechanisms of disease: the protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
202. Mendelsohn ME, Karas RH 2005 Molecular and cellular basis of cardiovascular gender differences. Science 308:1583-1587
203. Stumpf WE, Sar M, Aumuller G 1977 The heart: a target organ for estradiol. Science 196:319-321
204. McGill Jr HC, Anselmo VC, Buchanan JM, Sheridan PJ 1980 The heart is a target organ for androgen. Science 207:775-777
205. Horwitz KB, Horwitz LD 1982 Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 69:750-758
206. Ingegno MD, Money SR, Thelmo W, Greene GL, Davidian M, Jaffe BM, Pertschuk LP 1988 Progesterone receptors in the human heart and great vessels. Lab Invest 59:353-356
207. Karas RH, Patterson BL, Mendelsohn ME 1994 Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 89:1943-1950
208. Venkov CD, Rankin AB, Vaughan DE 1996 Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 94:727-733
209. Caulin-Glaser T, Watson CA, Pardi R, Bender JR 1996 Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 98:36-42
210. Cudeville C, Mondon F, Robert B, Rebourcet R, Mignot TM, Benassayag C, Ferre F 2000 Evidence for progesterone receptors in the human fetoplacental vascular tree. Biol Reprod 62:759-765
211. Diano S, Horvath TL, Mor G, Register T, Adams M, Harada N, Naftolin F 1999 Aromatase and estrogen receptor immunoreactivity in the coronary arteries of monkeys and human subjects. Menopause 6:21-28
212. Bayard F, Clamens S, Meggetto F, Blaes N, Delsol G, Faye JC 1995 Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 136:1523-1529
213. Sasano H, Murakami H, Shizawa S, Satomi S, Nagura H, Harada N 1999 Aromatase and sex steroid receptors in human vena cava. Endocr J 46:233-242
214. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L 2002 Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Natl Acad Sci USA 99:4055-4060
215. Simpson ER, Davis SR 2001 Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142:4589-4594
216. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y 1999 Localized expression of aromatase in human vascular tissues. Circ Res 84:1285-1291
217. Mendelsohn ME, Rosano GM 2003 Hormonal regulation of normal vascular tone in males. Circ Res 93:1142-1145
218. Sudhir K, Komesaroff PA 1999 Clinical review 110: cardiovascular actions of estrogens in men. J Clin Endocrinol Metab 84:3411-3415
219. Lew R, Komesaroff P, Williams M, Dawood T, Sudhir K 2003 Endogenous estrogens influence endothelial function in young men. Circ Res 93:1127-1133
220. Huhtaniemi I 1995 Molecular aspects of the ontogeny of the pituitary-gonadal axis. Reprod Fertil Dev 7:1025-1035
221. Barker DJP 1995 Fetal origins of coronary heart disease. BMJ 311:171-174
222. Oren A, Vos LE, Uiterwaal CS, Gorissen WH, Grobee DE, Bots ML 2006 Birth weight and carotid intimal-media thickness: new perspectives from the atherosclerosis risk in young adults (ARYA) study. Ann Epidemiol 14:8-16
223. Khosrotehrani K, Bianchi DW 2005 Multi-lineage potential of fetal cells in maternal tissue: a legacy in reverse. J Cell Sci 118:1559-1563
224. Muller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, Breyer T, Holubarsch C, Buettner R, Schule R 2000 FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 19:359-369
225. Yuan Y, Liao L, Tulis DA, Xu J 2002 Steroid receptor coactivator-3 is required for inhibition of neointima formation by estrogen. Circulation 105:2653-2659
226. Sullivan Jr TR, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell Jr TF, Mendelsohn ME 1995 Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96:2482-2488
227. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME 2002 Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ Res 90:1087-1092
228. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, O'Malley BW 2004 Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 15:937-949
229. Grumbach MM, Auchus RJ 1999 Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84:4677-4694
230. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP 1998 A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor α-deficient mice. J Clin Invest 102:1083-1091
231. Czubryt MP, McAnally J, Fishman GI, Olson EN 2003 Regulation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci USA 100:1711-1716
232. Repa JJ, Mangelsdorf DJ 2002 The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 8:1243-1248
233. Barish GD, Evans RM 2004 PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158-165
234. Lundholm L, Moverare S, Steffensen KR, Nilsson M, Otsuki M, Ohlsson C, Gustafsson JA, Dahlman-Wright K 2004 Gene expression profiling identifies liver X receptor α as an estrogen-regulated gene in mouse adipose tissue. J Mol Endocrinol 32:879-892
235. Clarkson TB 2002 The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med 47:61-68
236. LaRosa JC 1996 The pharmacology and effectiveness of specific lipid-active drugs: estrogen/sex steroids. Coron Artery Dis 7:683-688
237. Seed M, Knopp RH 2004 Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebocontrolled trials of hormone-replacement therapy. Curr Opin Lipidol 15:459-467
238. Gorodeski GI 2002 Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 16:329-355
239. Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS, Blumenthal RS 2002 Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. Chest 121:906-920
240. Kim RJ, Becker RC 2003 Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146:948-957
241. Herrington DM 2003 Role of estrogen receptor-α in pharmacogenetics of estrogen action. Curr Opin Lipidol 14:145-150
242. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray PF 2000 Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): testosterone regulates AR expression. Blood 95:2289-2296
243. Jayachandran M, Okano H, Chatrath R, Owen WG, McConnell JP, Miller VM 2004 Sex-specific changes in platelet aggregation and secretion with sexual maturity in pigs. J Appl Physiol 97:1445-1452
244. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, Lopez JA, Bray PF 2004 Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol 24:376-381
245. McGill Jr HC 1989 Sex steroid hormone receptors in the cardiovascular system. Postgrad Med, April, Spec No: 64-68
246. Forster C, Kietz S, Hultenby K, Warner M, Gustafsson JA 2004 Characterization of the ERβ-/- mouse heart. Proc Natl Acad Sci USA 101:14234-14239
247. Saunders PT, Maguire SM, Gaughan J, Millar MR 1997 Expression of oestrogen receptor β (ER β) in multiple rat tissues visualised by immunohistochemistry. J Endocrinol 154:R13-R16
248. Savolainen H, Frosen J, Petrov L, Aavik E, Hayry P 2001 Expression of estrogen receptor sub-types α and β in acute and chronic cardiac allograft vasculopathy. J Heart Lung Transplant 20:1252-1264
249. Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, Vetter H, Grohe C 2001 Activation of estrogen receptor β is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett 502:103-108
250. Grohé C, Kahlert S, Löbbert K, Vetter H 1998 Expression of oestrogen receptor α and β in rat heart: role of local oestrogen synthesis. J Endocrinol 156:R1-R7
251. Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J 2001 Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci USA 98:11765-11770
252. Pedram A, Razandi M, Aitkenhead M, Levin ER 2005 Estrogen inhibits cardiomyocyte hypertrophy in vitro: antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 280:26339-26348
253. Shain SA, Lin AL, McGill Jr HC 1988 Steroid receptors in the cardiovascular system: potential physiologic significance. In: Sheridan PJ, Blum K, Trachtenberg MC, eds. Steroid receptors and disease: cancer, autoimmune, bone and circulatory disorders. New York: Marcel Dekker, Inc.; 549-567
254. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ 1998 Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 98:256-261
255. Thum T, Borlak J 2002 Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537-1549
256. Villareal RP, Woodruff AL, Massumi A 2001 Gender and cardiac arrhythmias. Tex Heart Inst J 28:265-275
257. Larsen JA, Kadish AH 1998 Effects of gender on cardiac arrhythmias. J Cardiovasc Electrophysiol 9:655-664
258. Pham TV, Rosen MR 2002 Sex, hormones, and repolarization. Cardiovasc Res 53:740-751
259. Nagy E, Orvos H, Bardos G, Molnar P 2000 Gender-related heart rate differences in human neonates. Pediatr Res 47:778-780
260. Brouillette J, Rivard K, Lizotte E, Fiset C 2005 Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res 65:148-157
261. Barnard DD 2005 Heart failure in women. Curr Cardiol Rep 7:159-165
262. Lund LH, Mancini D 2004 Heart failure in women. Med Clin North Am 88:1321-1345
263. Golden KL, Marsh JD, Jiang Y 2004 Testosterone regulates mRNA levels of calcium regulatory proteins in cardiac myocytes. Horm Metab Res 36:197-202
264. Vizgirda VM, Wahler GM, Sondgeroth KL, Ziolo MT, Schwertz DW 2002 Mechanisms of sex differences in rat cardiac myocyte response to β-adrenergic stimulation. Am J Physiol Heart Circ Physiol 282:H256-H263
265. Xin HB, Senbonmatsu T, Cheng DS, Wang YX, Copello JA, Ji GJ, Collier ML, Deng KY, Jeyakumar LH, Magnuson MA, Inagami T, Kotlikoff MI, Fleischer S 2002 Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 416:334-338
266. McEwen BS, Alves SE 1999 Estrogen actions in the central nervous system. Endocr Rev 20:279-307
267. McCarthy MM, Konkle AT 2005 When is a sex difference not a sex difference? Front Neuroendocrinol 26:85-102
268. Toran-Allerand CD 2005 Estrogen and the brain: beyond ER-α, ER-β, and 17β-estradiol. Ann NY Acad Sci 1052:136-144
269. Garcia-Segura LM, McCarthy MM 2004 Minireview: role of glia in neuroendocrine function. Endocrinology 145:1082-1086
270. Garcia-Ovejero D, Azcoitia I, DonCarlos LL, Melcangi RC, Garcia-Segura LM 2005 Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res Brain Res Rev 48:273-286
271. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D 2003 Effect of estrogen plus progestin on global cognitive function in postmenopausal women. JAMA 289:2663-2672
272. Shumaker SA, Legault C, Rapp SR, Thal LJ, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Annlouise RA, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J 2003 Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. JAMA 289:2651-2662
273. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ 2003 Effect of estrogen plus progestin on stroke in postmenopausal women. JAMA 289:2673-2684
274. Ogita H, Node K, Asanuma H, Sanada S, Liao Y, Takashima S, Asakura M, Mori H, Shinozaki Y, Hori M, Kitakazi M 2002 Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol 40:998-1005
275. Ciriza I, Carrero P, Azcoitia I, Lundeen SG, Garcia-Segura LM 2004 Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J Neurobiol 61:209-221
276. Lacreuse A, Wilson ME, Herndon JG 2002 Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys. Neurobiol Aging 23:589-600
277. Nilsen J, Mor G, Naftolin F 1998 Raloxifene induces neurite outgrowth in estrogen receptor positive PC12 cells. Menopause 2:211-216
278. O'Neill K, Chen S, Brinton RD 2004 Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 185:63-80
279. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E 2001 Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats. Neurosci Lett 311:149-152
280. Bethea CL, Mirkes SJ, Su A, Michelson D 2002 Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 27:431-445
281. Pinilla L, Barreiro ML, Gonzalez LC, Tena-Sempere M, Aguilar E 2002 Comparative effects of testosterone proprionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat. J Endocrinol 172:441-448
282. Rossberg MI, Murphy SJ, Traystman RJ, Hurn PD 2000 LY353381.HCI, a selective estrogen receptor modulator, and experimental stroke. Stroke 31:3041-3046
283. Yaffe K, Krueger K, Cummings SR, Blackwell T, Henderson VW, Sarkar S, Ensrud K, Grady D 2005 Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am J Psychiatry 162:683-690
284. Mayer LP, Pearsall NA, Christian PJ, Cevine PJ, Payne CM, McCluskey MK, Marion SL, Sipes IG, Hoyer PB 2002 Long-term effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide. Reprod Toxicol 16:775-781
285. Thompson KE, Bourguet SM, Christian PJ, Benedict JC, Sipes IG, Flaws JA, Hoyer PB 2005 Differences between rats and mice in the involvement of the aryl hydrocarbon receptor in 4-vinylcyclohexene diepoxide-induced ovarian follicle loss. Toxicol Appl Pharmacol 203:114-123
286. Jacobson CD, Gorski RA 1981 Neurogenesis of the sexually dimorphic nucleus of the preoptic area of the rat. J Comp Neurol 196:519-529
287. Arai Y, Murakami S, Nishizuka M 1994 Androgen enhances neuronal degeneration in the developing preoptic area: apoptosis in the anteroventral periventricular nucleus (AVPvN-POA). Horm Behav 28:313-319
288. Breedlove SM 1985 Hormonal control of the anatomical specificity of motoneuron to muscle innervation in rats. Science 227:1357-1359
289. Sengelaub DR, Arnold AP 1986 Development and loss of early projections in a sexually dimorphic rat spinal nucleus. J Neurosci 6:1613-1620
290. Jordan CL, Letinsky MS, Arnold AP 1989 The role of gonadal hormones in neuromuscular synapse elimination in rats. I. Androgen delays the loss of multiple innervation in the levator ani muscle. J Neurosci 9:229-238
291. Mong JA, Glaser E, McCarthy MM 1999 Gonadal steroids promote glial differentiation and alter neuronal morphology in the developing hypothalamus in a regionally specific manner. J Neurosci 19:1464-1472
292. Toran-Allerand CD, Singh M, Setalo G 1999 Novel mechanisms of estrogen action in the brain: new players in an old story. Front Neuroendocrinol 20:97-121
293. Beyer C 1999 Estrogen and the developing mammalian brain. Anat Embryol 199:379-390
294. Woolley CS 1999 Effects of estrogen in the CNS. Curr Opin Neurobiol 9:345-354
295. Cooke BM, Woolley CS 2004 Gonadal hormone modulation of dendrites in the mammalian CNS. J Neurobiol 64:34-46
296. Hao J, Rapp PR, Leffler AE, Leffler SR, Janssen WG, Lou W, Mckay H, Roberts JA, Wearne SL, Hof PR, Morrison JH 2006 Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. J Neurosci 26:2571-2578
297. Emerson CS, Headrick JP, Vink R 1993 Estrogen improves biochemical and neurologic outcome following traumatic brain injury in male rats, but not in females. Brain Res 608:95-100
298. Saiyed M, Riker WK 1993 Cholinergic and anticholinergic drug effects on survival during hypoxia: significant gender differences. J Pharmacol Exp Ther 264:1146-1153
299. Nishikawa T, Kirsch JR, Koehler RC, Miyabe M, Traystman RJ 1994 Competitive N-methyl-D-aspartate receptor blockade reduces brain injury following transient focal ischemia in cats. Stroke 25:2258-2264
300. L expression and β-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem 72:1552-1563
301. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM 1998 Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 18:1253-1258
302. Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS, London ED, Klaus JA, Hurn PD 1999 17β-Estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 30:1665-1670
303. Simpkins JW, Rajakumar G, Zhang Y-Q, Simpkins CE, Greenwald D, Yu CJ, Bodor N, Day AL 1997 Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 87:724-730
304. Hall ED, Pazara KE, Linseman KL 1991 Sex differences in post-ischemic neuronal necrosis in gerbils. J Cereb Blood Flow Metab 11:292-298
305. Zhang Y-Q, Shi J, Rajakumar G, Day AL, Simpkins JW 1998 Effects of gender and estradiol treatment on focal brain ischemia. Brain Res 784:321-324
306. Wang Q, Santizo R, Baughman VL, Pelligrino DA, Iadecola C 1999 Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke 30:630-637
307. Alkayed NJ, Harukuni I, Kimes AS, London ED, Traystman RJ, Hurn PD 1998 Gender-linked brain injury in experimental stroke. Stroke 29:159-166
308. Yang S-H, Shi J, Day AL, Simpkins JW 2000 Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 31:745-750
309. Back T, Ginsberg MD, Dietrich WD, Watson BD 1996 Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: effect on infarct morphology. J Cereb Blood Flow Metab 16:202-213
310. Green PS, Gridley KE, Simpkins JW 1996 Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218:165-168
311. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Javonovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S 1998 Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med 4:447-451
312. Fader AJ, Hendricson AW, Dohanich GP 1998 Estrogen improves performance of reinforced t-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally. Neurobiol Learn Mem 69:225-240
313. Gridley KE, Green PS, Simpkins JW 1997 Low concentrations of estradiol reduce β-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 778:158-165
314. Vedder H, Anthes N, Stumm G, Wurz C, Behl C, Krieg JC 1999 Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J Neurochem 72:2531-2538
315. Zaulyanov LL, Green PS, Simpkins JW 1999 Glutamate receptor requirement for neuronal cell death from anoxia-reoxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens. Cell Mol Neurobiol 19:705-718
316. Wilson ME, Dubal DB, Wise PM 2000 Estradiol protects against injury-induced cell death in cortical explant cultures: a role for estrogen receptors. Brain Res 873:235-242
317. Regan RF, Guo Y 1997 Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain Res 764:133-140
318. Singer CA, Figueroa-Masot CD, Batchelor RH, Dorsa DM 1999 The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci 19:2455-2463
319. Weaver Jr CE, Park-Chung M, Gibbs TT, Farb DH 1997 17-β-Estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res 761:338-341
320. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM 1999 Estradiol modulates Bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci 19:6385-6393
321. Rau SW, Dubal DB, Böttner M, Wise PM 2003 Estradiol differentially regulates c-Fos after focal cerebral ischemia. J Neurosci 23:10487-10494
322. Singer CA, Rogers KL, Dorsa DM 1998 Modulation of Bcl-2 expression: a potential component of estrogen protection in NT2 neurons. Neuroreport 9:2565-2568
323. Singh M, Setalo G, Guan X, Frail DE, Toran-Allerand CD 2000 Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-α knock-out mice. J Neurosci 20:1694-1700
324. Fitzpatrick JL, Mize AL, Wade CB, Harris JA, Shapiro RA, Dorsa DM 2002 Estrogen-mediated neuroprotection against β-amyloid toxicity requires expression of estrogen receptor α or β and activation of the MAPK pathway. J Neurochem 82:674-682
325. Wilson ME, Liu Y, Wise PM 2002 Estradiol enhances Akt activation in cortical explant cultures following neuronal injury. Mol Brain Res 102:48-54
326. Singh M, Setalo Jr G, Guan X, Warren M, Toran-Allerand CD 1999 Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 19:1179-1188
327. Murphy DD, Segal M 1997 Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA 94:1482-1487
328. Zhou Y, Watters JJ, Dorsa DM 1996 Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology 137:2163-2166
329. Woolley CS, McEwen BS 1992 Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 12:2549-2554
330. Dubal DB, Zhu B, Yu B, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM 2001 Estrogen receptor-α, not -β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 98:1952-1957
331. Miranda RC, Sohrabji F, Toran-Allerand CD 1993 Neuronal colocalization of mRNAs for neurotrophins and their receptors in the developing central nervous system suggests a potential for autocrine interactions. Proc Natl Acad Sci USA 90:6439-6443
332. Murphy DD, Cole NB, Segal M 1998 Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA 95:11412-11417
333. Murphy DD, Cole NB, Greenberger V, Segal M 1998 Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 18:2550-2559
334. Murphy DD, Segal M 1996 Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J Neurosci 16:4059-4068
335. Duenas M, Torres-Aleman I, Naftolin F, Garcia-Segura LM 1996 Interaction of insulin-like growth factor-I and estradiol signaling pathways on hypothalamic neuronal differentiation. Neuroscience 74:531-539
336. Naftolin F, Leranth C, Horvath TL, Garcia-Segura LM 1996 Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticity. Cell Mol Neurobiol 16:213-223
337. Pelligrino DA, Galea E 2002 Estrogen and cerebrovascular physiology and pathophysiology. Japan J Pharmacol 86:137-158
338. Subbiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski A 1993 Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 77:1095-1097
339. Green PS, Gridley KE, Simpkins JW 1998 Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience 84:7-10
340. Culmsee C, Vedder H, Ravati A, Junker V, Otto D, Ahlemeyer B, Krieg J-C, Krieglstein J 1999 Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab 19:1263-1269
341. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ, Holsboer F 1997 Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 51:535-541
342. Fassbender K, Masters C, Beyreuther K 2000 Alzheimer's disease: an inflammatory disease? Neurobiol Aging 21:433-436
343. Stoll G, Jander S, Schroeter M 2002 Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 513:87-113
344. Allen SM, Rothwell NJ 1996 Cytokines and acute neurodegeneration. Nat Rev Neurosci 2:734-744
345. Mergenthaler P, Dirnagl U, Meisel A 2004 Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 19:151-167
346. Streit WJ 2002 Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40:133-139
347. Maggi A, Ciana P, Brusadelli A, Belcredito S, Bonincontro C, Vegeto E 2001 Are there biological bases for a beneficial effect of estrogens in neural diseases? Horm Behav 40:203-209
348. Maggi A, Ciana P, Belcredito S, Vegeto E 2004 Estrogens in the nervous system: mechanisms and nonreproductive functions. Annu Rev Physiol 66:291-313
349. Vegeto E, Bonincontro C, Pollio G, Sala A, Viappiani S, Nardi F, Brusadelli A, Viviani B, Ciana P, Maggi A 2001 Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 21:1809-1818
350. Stoll G, Jander S, Schroeter M 1998 Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 56:149-171
351. Danton GH, Dietrich WD 2003 Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62:127-136
352. Cuzzocrea S, Mazzon E, Sautebin L, Serraino I, Dugo L, Calabro G, Caputi AP, Maggi A 2001 The protective role of endogenous estrogens in carrageenan-induced lung injury in the rat. Mol Med 7:478-487
353. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC 2004 Anatomy of the estrogen response element. Trends Endocrinol Metab 15:73-78
354. McDonnell DP 2003 Mining the complexities of the estrogen signaling pathways for novel therapeutics. Endocrinology 144:4237-4240
355. del Zoppo G, Ginis I, Hallenbeck JM, Iadecola C, Wang X, Feurstein GZ 2000 Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10:95-112
356. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME 1997 Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 17:9157-9164
357. Nagayama M, Abert T, Nagayama T, Ross ME, Iadecola C 1999 Age-dependent increase in ischemic brain injury in wild-type mice and in mice lacking the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 19:661-666
358. Iadecola C, Zhang F, Xu S, Casey R, Ross ME 1995 Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 15:378-384
359. Sugimoto K, Iadecola C 2002 Effects of aminoguanidine on cerebral ischemia in mice: comparison between mice with and without inducible nitric oxide synthase gene. Neurosci Lett 331:25-28
360. Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffarth GU, Grau AM, Green FR, Grond-Ginsbach C, Schwaninger M 2003 Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 34:1864-1870
361. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, Hennerici M 1994 Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 122:135-139
362. Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V 2001 Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci 22:289-296
363. Hanisch U-K 2002 Microglia as a source and target of cytokines. Glia 40:140-155
364. Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, Offner H 2001 17 β-Estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J Neurosci Res 65:529-542
365. Salem ML 2004 Estrogen, a double-edged sword: modulation of the TH1- and TH2-mediated inflammations by differential regulation of TH1/TH2 cytokine production. Curr Drug Targets Inflamm Allergy 3:97-104
366. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, Lysko PG, Feuerstein GZ 1997 Tumor necrosis factor-α: a mediator of focal ischemic brain injury. Stroke 28:1233-1244
367. Hallenbeck JM 2002 The many faces of tumor necrosis factor in stroke. Nat Med 8:1363-1368
368. Shohami E, Ginis I, Hallenbeck JM 1999 Dual role of tumor necrosis factor α in brain injury. Cytokine Growth Factor Rev 10:119-130
369. Santizo RA, Xu HL, Ye S, Baughman VL, Pelligrino DA 2001 Loss of benefit from estrogen replacement therapy in diabetic ovariectomized female rats subjected to transient forebrain ischemia. Brain Res 956:86-95
370. Harukuni I, Hurn PD, Crain BJ 2001 Deleterious effect of β-estradiol in a rat model of transient forebrain ischemia. Brain Res 900:137-142
371. Kondo Y, Suzuki K, Sakuma Y 1997 Estrogen alleviates cognitive dysfunction following transient brain ischemia in ovariectomized gerbils. Neurosci Lett 238:45-48
372. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E 2003 Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138:1-9
373. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH 2004 Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291:2947-2958
374. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw AE 2003 The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13:18-77
375. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, Bowen D, Terrell T, Jones BN 1998 The Women's Health Iniative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials 19:604-621
376. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D 2003 Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60:1089-1093
377. Tang Y, Hao J, Mckay H, Allen PB, Rapp PR, Hof PR 2004 Estrogen replacement increases spinopilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex 14:215-223
378. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS 2002 Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 288:2123-2129
379. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A 1999 Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52:78-84
380. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R 1996 Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348:429-432
381. Resnick SM, Henderson VW 2002 Hormone therapy and risk of Alzheimer's disease: a critical time. JAMA 288:2170-2172
382. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA 2005 Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J Neurol Neurosurg Psychiatry 76:103-105
383. Henderson VW, Guthrie JR, Dudley EC, Burger HG, Dennerstein L 2003 Estrogen exposures and memory at midlife. Neurology 60:1369-1371
384. Sherwin BB 1988 Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13:345-357
385. Sherwin BB, Tulandi T 1996 "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 81:2545-2549
386. Phillips SM, Sherwin BB 1992 Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17:485-495
387. Woo J, Lau E, Ho SC, Cheng F, Chan C, Chan ASY, Haines CJ, Chan TYK, Li M, Sham A 2003 Comparison on pueraria lobata with hormone replacement therapy in treating the adverse health consequence of menopause. Menopause 10:352-361
388. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI 2005 Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 192:387-393
389. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM 2001 Effects of hormone replacement therapy on cognitive performance in elderly women. Maturitas 38:137-146
390. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Conner E 2002 Effect of postmenopausal hormone therapy on cognitive function: the heart and estrogen/progestin replacement study. Am J Med 113:543-548
391. Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA 2006 Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 91:1802-1810
392. Scott H, Laake K 2001 Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev (4):CD003160
393. Zamrini E, McGwin G, Roseman JF 2004 Association between statin use and Alzheimer's disease. Neuroepidemiology 23:94-98
394. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N 2005 KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8:3-12
395. Adams MM, Shah RA, Janssen WG, Morrison JH 2001 Different modes of hippocampal plasticity in young and aged female rats. Proc Natl Acad Sci USA 98:8071-8076
396. Markowska AL, Savonenko AV 2002 Effectiveness of estrogen replacement in restoration of cognitive function after long-term estrogen withdrawal in aging rats. J Neurosci 22:10985-10995
397. Savonenko AV, Markowska AL 2003 The cognitive effects of ovariectomy and estrogen replacement are modulated by aging. Neuroscience 119:821-830
398. Rapp PR, Morrison JH, Roberts JA 2003 Cyclic estrogen replacement improves cognitive function in aged ovariectomized rhesus monkeys. J Neurosci 23:5708-5714
399. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Conner E, Cox DA, Nickelsen T 2001 Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 344:1207-1213
400. Paganini-Hill A, Clark LJ 2000 Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165-176
401. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA 2004 Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955-969
402. Breuer B, Anderson R 2000 The relationship of tamoxifen with dementia, depression, and dependence in activities of daily living in elderly nursing home residents. Women Health 31:71-85
403. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S 2004 Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61-66
404. Linzmayer L, Semlitsch HV, Saletu B, Bock G, Saletu-Zyhlarz G, Zoghlami A, Gruber D, Metka M, Huber J, Oettel M, Graser T, Grunberger J 2001 Double-blind, placebo-controlled psychometric studies on the effects of a combined estrogen-progestin regimen versus estrogen alone on performance, mood and personality of menopausal syndrome patients. Arzneimittelforschung 51:238-245
405. Saletu-Zyhlarz G, Anderer P, Gruber G, Mandl M, Gruber D, Metka M, Huber J, Oettel M, Graser T, Abu-Bakr MH, Gratzhofer E, Saletu B 2003 Insomnia related to postmenopausal syndrome and hormone replacement therapy: sleep laboratory studies on baseline differences between patients and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone. J Sleep Res 12:239-254
406. Haas JS, Kaplan CP, Gerstenberger EP, Kerlikowske K 2004 Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Int Med 140:184-188
407. Strandberg TE, Ylikorkala O, Tikkanen MJ 2003 Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. Am J Cardiol 92:212-214
408. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H 2001 Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85:619-625
409. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I 2003 Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41:1358-1363
410. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL 1986 Biological effects of transdermal estradiol. N Engl J Med 314:1615-1620
411. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T 2002 Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106:1771-1776
412. Demirol A, Baykal C, Kirazli S, Ayhan A 2001 Effects of hormone replacement on hemostasis in spontaneous menopause. Menopause 8:135-140
413. Duschek EJ, Neele SJ, Thomassen MC, Rosing J, Netelenbos C 2004 Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. Blood Coagul Fibrinolysis 15:649-655
414. Kelly JJ, Rajkovic IA, O'Sullivan AJ, Sernia C, Ho KK 1993 Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin Endocrinol (Oxf) 39:561-567
415. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK 1998 The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102:1035-1040
416. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell Jr DR 1982 Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144:511-518
417. Vehkavaara S, Hakala-Ala-Pietilä T, Virkamäki A, Bergholm R, Ehnholm C, Hovatta O, Taskinen M-R, Yki-Järvinen H 2000 Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102:2687-2693
418. Harvey PJ, Morris BL, Miller JA, Floras JS 2005 Estradiol induces discordant angiotensin and blood pressure responses to orthostasis in healthy postmenopausal women. Hypertension 45:399-405